Nuvo Research Inc. is a publicly traded, pharmaceutical company headquartered in Mississauga, Ontario with manufacturing facilities located in Varennes, Quebec and Wanzleben, Germany, and research and development facilities in San Diego, California
and Leipzig, Germany.
Nuvo is focused on the research and development of drug
products using its topical and transdermal drug delivery technologies. The Company develops drugs based on two technology platforms: transdermal drug delivery and immune system regulation.
Nuvo markets two products Pennsaid®, a topical non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis
of the knee and Oxoferin™, a topical wound healing agent.
In June 2009, Nuvo entered into a license and development agreement with Mallinckrodt Inc., a subsidiary of Covidien (NYSE:COV), granting it exclusive rights to market and sell Pennsaid, and its follow-on product, Pennsaid Plus, in the United States.
In November 2009, the U.S. Food and Drug Administration (FDA) approved
Nuvo's New Drug Application for Pennsaid allowing Covidien to market and sell Pennsaid
in the U.S which commenced in late April 2010.
|
